Capture réglementaire en temps de pandémie
In the midst of the covid-19 pandemic, the Food and Drug Administration (FDA) published in March the orphan drug status granted to remdesivir, a molecule patented by Gilead as a treatment for the new coronavirus. This gave the company seven years of market exclusivity for its drug in the US market....
Main Author: | Samira Guennif |
---|---|
Format: | Article |
Language: | English |
Published: |
Association Recherche & Régulation
2021-02-01
|
Series: | Revue de la Régulation |
Subjects: | |
Online Access: | http://journals.openedition.org/regulation/17621 |
Similar Items
-
A regulatory capture explanation of South Africa's private health insurance legislation
by: Hutcheson, Hugh-David
Published: (2012) -
Late 20th-Century Consumer Advocacy, Pharmaceuticals, and Public Health: Public Citizen's Health Research Group in Historical Perspective
by: Alkon, Ava Elyse
Published: (2012) -
Causes et conséquences de l'arbitrage règlementaire
by: Lermyte, Jason
Published: (2015) -
Diagnostic of Operational Systems in the Pharmaceutic Industry in Pandemy
by: Vasilică Rusu
Published: (2020-01-01) -
Les convergences parallèles : une économie politique de la régulation de l'accès au marché des médicaments en France et en Angleterre
by: Benoît, Cyril
Published: (2016)